US Executive Officer Management Changes SEC — April 30, 2026

30-04-2026

At the 2026 Annual Meeting of Stockholders on April 30, 2026, bioAffinity Technologies, Inc. stockholders elected six directors (Maria Zannes, Steven Girgenti, Peter Knight, Jamie Platt, Jamie Platt, Roberto Rios, and John J. Oppenheimer) and approved all ten proposals, including ratification of WithumSmith+Brown, PC as auditors, warrant exercise and anti-dilution adjustments, amendment to the 2024 Equity Incentive Compensation Plan increasing reserved shares to 1,000,000 from 66,666, authorization for non-public offerings, and a discretionary reverse stock split in the range of 1-for-2 to 1-for-250. Voting showed majority support for all items among 4,498,675 shares outstanding, though some proposals like the Plan Amendment (Proposal 6) had closer margins with 131,076 votes against. No adjournments were needed as all proposals passed.

• ·Proposal 9 (Reverse Stock Split): 1,211,478 votes for, 491,041 against, 15,490 abstentions.
• ·Proposal 6 (Plan Amendment): 318,231 votes for, 131,076 against, 4,350 abstentions.
• ·Proxy Statement filed March 16, 2026; Record Date March 13, 2026.

30-04-2026

Bonk, Inc. (NASDAQ:BNKK) appointed founder Mitchell Rudy (Nom) as President, while he retains his Board seat, to drive a three-pillar mandate: path to profitability via high-margin digital revenue, targeted accumulation to 5% ownership of BONK digital asset supply, and direct business incubation. The company is expanding into Real-World Asset (RWA) capabilities, prediction markets, and social betting verticals, building on partnerships like dYdX for BONK.trade and addressing the gap between market cap and its $30 million interest in BONK.fun. CEO Jarrett Boon highlighted Rudy's role in executing the digital pivot with precision.

• ·Announcement date: April 29, 2026
• ·Company location: Scottsdale, AZ
• ·Operates revenue-generating assets in Solana ecosystem

30-04-2026

On April 26, 2026, Regional Health Properties, Inc. appointed Marlie Davis, CPA, MBA, as Chief Financial Officer effective May 1, 2026; she brings over 20 years of finance, accounting, audit, and real estate investment experience from roles at Hatteras Sky and other firms. Compensation includes an initial annual base salary of $265,000, target bonus of $100,000, 35,000 restricted stock units, and options for 35,000 shares. Separately, Director Christopher Winkle resigned effective May 31, 2026, not due to any disagreement with the company.

• ·Ms. Davis is age 55, holds an MBA from Utica College and BBA in Accounting from University of Central Florida.
• ·No arrangements, family relationships, or material interests under Item 404(a) for Ms. Davis.
• ·Employment is at-will with nine months severance upon termination without cause.

30-04-2026

Chemours held its annual shareholder meeting on April 24, 2026, where all 11 director nominees were elected with strong support ranging from 95.8% to 99.3% of votes cast. Shareholders also approved the 2026 Equity and Incentive Plan (reserving a maximum of 6,375,275 shares), the advisory say-on-pay vote, and ratification of PricewaterhouseCoopers LLP as independent auditors, with no material opposition noted across proposals.

• ·Proposal 2 (say-on-pay): 110,058,427 For, 2,527,583 Against, 229,523 Abstain.
• ·Proposal 3 (Equity Plan): 108,842,885 For, 3,734,567 Against, 238,082 Abstain.
• ·Proposal 4 (Auditor Ratification): 128,312,790 For, 813,925 Against, 182,394 Abstain (no broker non-votes).

30-04-2026

Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino, an experienced biotech executive with prior roles at Intellia Therapeutics, Vertex Pharmaceuticals, Alnylam, and Merck, to its board of directors effective April 28, 2026, with her term expiring at the 2028 Annual Meeting of Stockholders. She was also appointed to the Science and Technology Committee. Compensation includes $40,000 annual cash retainer plus an initial stock option for 50,000 shares and future annual grants of 25,000 shares starting in 2027.

• ·Dr. Sepp-Lorenzino, age 65, holds a Ph.D. in biochemistry from New York University and has extensive experience in genomic medicine, nucleic acid therapies, and oncology.
• ·No arrangements or understandings with other persons for her appointment; no family relationships with directors or officers.
• ·Standard indemnification agreement with the Company; no material interests under Item 404(a) of Regulation S-K.

30-04-2026

Entegris, Inc. (NASDAQ: ENTG) announced the appointment of Sukhi Nagesh as Chief Financial Officer effective May 18, 2026, bringing nearly 30 years of finance, investor relations, and corporate development experience from Nielsen, GlobalFoundries, Marvell Technology, Applied Materials, Brooks Automation, and Asyst Technologies. The appointment follows a rigorous search, with CEO Dave Reeder praising Nagesh's industry expertise. Mike Sauer, Interim CFO since March 1, 2026, transitions back to VP, Chief Accounting Officer.

• ·Entegris has manufacturing, customer service and/or research facilities in the United States, Canada, China, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan.
• ·Entegris is ISO 9001 certified.

30-04-2026

Fermi Inc., a Real Estate Investment Trust, appointed Robert L. Masson as Interim Chief Financial Officer and principal financial officer effective April 29, 2026, until a permanent successor is named. Mr. Masson, age 55, has over 20 years of finance executive experience in aerospace, defense, and industrial sectors, including prior CFO roles at Noble Supply and Logistics, Latham Group, Inc., Hypertherm, Inc., and others. No compensation arrangements have been approved, and there are no related understandings, family relationships, or material conflicts disclosed.

• ·Mr. Masson served as CFO of Noble Supply and Logistics from 2023-2025, CFO of Latham Group from 2022-2023, EVP and CFO of Hypertherm from 2018-2022, VP of Finance at Flowserve from 2016-2018, and various finance roles at Raytheon Technologies from 2003-2016.
• ·Mr. Masson began career as Lieutenant and Naval Aviator in U.S. Navy (1992-2001).
• ·Holds Bachelor of Science in Economics from United States Naval Academy and MBA from Harvard Business School.
• ·Company is an emerging growth company and lists common stock ($0.001 par value) on Nasdaq (FRMI) and London Stock Exchange.

30-04-2026

Moving iMage Technologies, Inc. appointed Bart Bedard as Chief Financial Officer effective April 27, 2026, reporting to Francois Godfrey, President & COO, with responsibilities including financial operations, SEC compliance, and process automation. Compensation includes a $200,000 annual base salary, $10,000 signing bonus, 75,000 stock options (25% vesting immediately, remainder over three years), and benefits like 401(k), healthcare, and four weeks vacation. Transition support from Bill Greene is planned through Q3 close (March 31), Q1 10-Q (mid-May), and 10-K (October 2026).

• ·Stock options include immediate 25% vesting and remaining 75% in equal annual installments over three years; full vesting upon change of control.
• ·Signing bonus subject to pro-rata repayment if voluntary resignation within 12 months.
• ·Transition: Bill Greene active through Q3 close (March 31), part-time through Q1 10-Q (mid-May), light advisory through 10-K (October 2026).

30-04-2026

CCC Intelligent Solutions Holdings Inc. announced that Brian Herb, Executive Vice President and Chief Financial & Administrative Officer, will depart effective May 25, 2026, with Rodney Christo, Senior Vice President of Finance & Chief Accounting Officer with over 30 years at CCC, assuming the interim CFO role for continuity. Q1 2026 financial results showed revenue of $281.3 million, up 12% YoY from Q1 2025, and adjusted EBITDA of $120.2 million, up 21% YoY from $99.1 million. No declines or flat metrics were reported, supporting ongoing growth amid the leadership transition.

• ·Brian Herb will continue to support the company as an advisor post-departure.
• ·Rodney Christo has served CCC in positions of increasing responsibility for more than 30 years.

30-04-2026

BorgWarner Inc. (NYSE: BWA) declared a quarterly cash dividend of $0.17 per share of common stock on April 29, 2026, payable on June 15, 2026, to stockholders of record on June 1, 2026. The announcement was included as Exhibit 99.1 in the company's 8-K filing dated April 30, 2026. No changes in dividend amount or other financial metrics were compared to prior periods in the release.

• ·Contact for inquiries: Patrick Nolan at 248.754.0884

30-04-2026

NeuroOne Medical Technologies Corporation announced that Ronald McClurg, its Chief Financial Officer, will retire from the officer role effective June 30, 2026, and transition to Senior Advisor until his full separation on December 31, 2026, under a Transition and Release Agreement. Christopher Volker, the current Chief Operating Officer, will succeed as Chief Financial Officer effective July 1, 2026, with his base salary increased to $350,000. The changes ensure a smooth transition with Volker's extensive medtech experience from Abbott, Cardiovascular Systems, Inc., and St. Jude Medical.

• ·Transition and Release Agreement dated April 28, 2026, provides McClurg continued salary and benefits through December 31, 2026, eligibility for FY2026 performance bonus if employed through September 30, 2026, and post-separation consulting services counting as 'Continuous Services' for equity vesting.
• ·McClurg resigns as officer effective July 1, 2026, when his role changes to Special Advisor.
• ·Volker's other compensatory terms remain unchanged; he holds CFA designation, BA from St. John’s University, and MBA from Wharton.

30-04-2026

On April 24, 2026, RLJ Lodging Trust held its Annual Meeting where shareholders elected nine trustees (Robert L. Johnson, Leslie D. Hale, Evan Bayh, Arthur R. Collins, Nathaniel A. Davis, Patricia L. Gibson, Robert M. La Forgia, Robert J. McCarthy, and Robin Zeigler), ratified PricewaterhouseCoopers LLP as independent auditors for FY ending December 31, 2026, approved named executive officer compensation on an advisory basis, and approved the 2026 Equity Incentive Plan providing for up to 4,763,000 common shares. All proposals passed with strong shareholder support, including over 106 million votes for each trustee nominee and 109,275,582 votes for the 2026 Plan. The 2026 Plan, adopted by the Board on March 13, 2026, replaces the 2021 Plan and terminates on the tenth anniversary of its April 24, 2026 effective date.

• ·Trustee election votes: Robert L. Johnson (107,517,178 For, 5,633,406 Against); Leslie D. Hale (112,021,180 For, 1,131,360 Against); all others over 106M For.
• ·Auditor ratification: 112,401,134 For, 5,980,919 Against, 33,353 Abstentions.
• ·Exec comp advisory: 99,057,306 For, 14,041,217 Against, 63,987 Abstentions.
• ·2026 Plan approval: 109,275,582 For, 3,835,789 Against, 51,139 Abstentions.
• ·Proxy Statement filed March 23, 2026; 2026 Plan to be filed in 10-Q for quarter ending June 30, 2026.

30-04-2026

Health Catalyst, Inc. (Nasdaq: HCAT) appointed Steve Nelson, Executive Vice President and President of Aetna (a CVS Health company), to its Board of Directors effective May 1, 2026, continuing leadership enhancements with Ben Albert as CEO and Justin Spencer as Chairman earlier in the year. Nelson brings extensive experience from roles at Aetna, ChenMed, Duly Health and Care, and UnitedHealthcare, aimed at accelerating the company's transformation in healthcare intelligence. The company is backed by $2.8 billion in documented outcomes.

• ·Filing references risk factors in 10-Q for quarter ended September 30, 2025 (filed November 10, 2025) and 10-K for year ended December 31, 2024 (filed February 26, 2025, amended April 30, 2025)

30-04-2026

On April 28, 2026, the Board of Directors of GrabAGun Digital Holdings Inc. nominated Marc Nemati, Matt Vittitow, Chris Cox, Andrew J. Keegan, Collins Idehen Jr., Blake Masters, Kelly Reisdorf, and Donald J. Trump Jr. for reelection at the 2026 annual meeting of shareholders, to serve until the 2027 annual meeting. Director Dusty Wunderlich, whose term expires at the upcoming meeting, will not stand for reelection by mutual agreement with the Nomination and Governance Committee. The Board expressed gratitude for Mr. Wunderlich's service.

• ·Filing date: April 30, 2026
• ·Event date: April 28, 2026
• ·Trading symbols: PEW (common stock, NYSE), PEWW (redeemable warrants, NYSE)
• ·Company is an emerging growth company
• ·Incorporated in Texas, EIN: 33-4289144, CIK: 0002051380

30-04-2026

Eos Energy Enterprises, Inc. announced the appointment of Alessandro Lagi as Chief Financial Officer effective June 8, 2026, replacing Nathan Kroeker who transitions from interim CFO to Chief Commercial Officer. Mr. Lagi, with prior roles at Johnson Controls and Baker Hughes, will receive a $470,000 base salary, $2,000,000 initial RSU grant, and $1,000,000 annual LTIP target. The move strengthens financial leadership with no reported disruptions.

• ·Employment Agreement dated April 28, 2026.
• ·Target annual bonus opportunity: 100% of base salary.
• ·Severance includes 12 months salary continuation, pro-rata bonus, and 12-month equity vesting acceleration.
• ·Post-termination restrictions: 12-month non-compete and non-solicit, perpetual non-disparagement.
• ·No arrangements, family relationships, or material interests under Item 404(a).

30-04-2026

Kirby Corporation reported Q1 2026 net earnings of $81.2 million ($1.50 per share, +13% YoY) and revenues of $844.1 million (+7.5% YoY), driven by 23% YoY revenue growth in coastal marine and 45% in power generation, while raising full-year EPS growth guidance to 5%-15%. However, inland marine revenues were flat YoY amid weather disruptions, distribution and services operating margin declined to 6.7% from 7.3%, and oil & gas revenues fell 25% YoY with operating income down 53%. The company acquired 23 barges and three boats for $95.8 million and repurchased $52.7 million in shares.

• ·Amended credit agreement on March 26, 2026: extended maturity to 2031, revolving facility to $750M, eliminated term loan.
• ·Debt-to-capitalization ratio 22.3% as of March 31, 2026.
• ·2026 full-year guidance: operating cash flow $575M-$675M, capex $220M-$260M; inland revenues low-to-mid single-digit growth, coastal mid-single-digit growth, distribution & services flat to slightly higher.

30-04-2026

Matrix Service Company announced the departures of CFO Kevin S. Cavanah and Chief Administrative Officer Nancy E. Austin as part of organizational changes ahead of Shawn P. Payne assuming the CEO role on July 1, 2026. Cavanah will continue through the filing of the FY2026 10-K for transition and receive a $771,000 lump sum severance payment plus equity vesting benefits upon separation. Austin will step down effective May 7, 2026, receiving a $608,345 lump sum severance payment, 18 months of COBRA coverage, and vesting of 20,368 restricted stock units; neither departure stems from disagreements.

• ·Cavanah to serve through earliest of one week post FY2026 10-K filing or termination without Cause.
• ·Both receive 18 months Company-paid COBRA coverage and performance units eligible for vesting based on actual performance.
• ·Cavanah Agreement signed April 29, 2026; Austin Agreement expected.
• ·New CFO to be based in Houston with Payne; CAO role eliminated, duties redistributed.

30-04-2026

Olin Corporation amended its bylaws effective April 30, 2026, with detailed provisions on shareholder meetings, including place, annual and special meeting rules, notice requirements (10-60 days), quorum (majority of votes), and voting procedures. The amendments impose strict advance notice requirements for shareholder-proposed business, such as 120-150 calendar days before the annual meeting anniversary for timely notices, along with extensive disclosure obligations regarding share ownership, derivatives, and material interests. No financial impacts or performance metrics are disclosed.

• ·Shareholder notice for annual meetings: not later than 120 calendar days or earlier than 150 calendar days before anniversary of prior annual meeting.
• ·Special meetings callable by Board, Chair, President, Secretary, or holders of majority of voting shares.
• ·Proxy solicitation by shareholders must use non-white proxy cards.

30-04-2026

On April 29, 2026, Cognex Corporation's Board determined that Joerg Kuechen will no longer be deemed an executive officer under SEC rules but will continue as Head of Mergers and Acquisitions. At the 2026 Annual Meeting of Shareholders on the same date, with 153,890,280 shares represented out of 167,013,856 outstanding, shareholders elected Matthew Moschner, Angelos Papadimitriou, and Christopher Donato as directors to serve until 2029, approved an amendment to the 2023 Stock Option and Incentive Plan, ratified KPMG LLP as independent auditors for fiscal 2026, and approved named executive officer compensation on an advisory basis, all as recommended by the Board.

• ·Director election votes - Matthew Moschner: For 136,554,604; Against 2,824,917; Abstained 107,328; Broker Non-Votes 14,403,431
• ·Director election votes - Angelos Papadimitriou: For 121,262,948; Against 18,115,308; Abstained 108,593; Broker Non-Votes 14,403,431
• ·Director election votes - Christopher Donato: For 134,157,408; Against 5,216,762; Abstained 112,679; Broker Non-Votes 14,403,431
• ·Stock plan amendment: For 135,582,856; Against 3,763,664; Abstained 140,329; Broker Non-Votes 14,403,431
• ·Auditor ratification: For 153,641,083; Against 83,521; Abstained 165,676
• ·Say-on-pay: For 109,615,176; Against 29,685,048; Abstained 186,625; Broker Non-Votes 14,403,431

30-04-2026

At its 2026 Annual Meeting of Stockholders on April 29, 2026, Claritev Corporation's stockholders elected four Class III directors (Anthony Colaluca, Jr., Michael S. Klein, Allen R. Thorpe, and Dale A. White) with strong support exceeding 90% of votes cast for each. Stockholders also ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026 (over 99% approval), approved an advisory vote on named executive officer compensation (~85% approval), and approved an amendment to the 2020 Omnibus Incentive Plan adding 2,375,000 shares to the reserve. All proposals passed with significant majorities and no notable opposition.

• ·Proposal 2 (auditor ratification): 6,243 votes AGAINST, 476 ABSTAIN.
• ·Proposal 3 (exec comp): 1,542,188 votes AGAINST, 14,726 ABSTAIN.
• ·Proposal 4 (plan amendment): 701,502 votes AGAINST, 8,339 ABSTAIN.
• ·Amendment filed as Exhibit 10.1.

30-04-2026

On April 24, 2026, the Compensation Committee of TechTarget, Inc.'s Board approved the Executive Incentive Growth Acceleration Plan (GAP) for the 2026-2028 period and the 2026 Executive Short-Term Incentive Plan (STIP). The GAP offers cash bonuses to covered executives based on annual CAGR revenue and operating profit margin targets, using synthetic shares valued 60% on TechTarget stock and 40% on Informa PLC stock, with share price floors at 50% and ceilings at 200% of grant date prices. The STIP ties bonuses 80% to revenue targets and 20% to operating profit targets, with payouts capped at 300% for non-CEO revenue and 150% for profit (CEO capped at 150% per metric).

• ·GAP bonuses banked annually for 2026-2028, with opportunity to earn back unbanked portions from first two years if maximum targets achieved later.
• ·STIP incremental payouts: each 1% above 100% target yields 10% incremental payout for non-CEO.
• ·No specific performance targets or base salary percentages disclosed.

30-04-2026

Analysis unavailable

30-04-2026

Marcus Corporation (NYSE: MCS) announced that Mark A. Gramz, president of Marcus Theatres, will retire on March 31, 2026, after 55 years of service, starting from a ticket taker role. A national search for his successor is underway, with Gramz to serve as an advisor post-retirement to ensure a smooth transition. CEO Gregory S. Marcus commended Gramz's leadership and contributions to the moviegoing experience.

• ·Marcus Theatres is the fourth largest theatre circuit in the U.S.
• ·Gramz promoted to president of Marcus Theatres in 2022; joined corporate team in 1990.
• ·Gramz received Salah M. Hassanein Humanitarian Award from ShowEast in October 2024.
• ·Announcement dated October 30, 2025.

30-04-2026

Match Group, Inc. appointed Raina Moskowitz to its Board of Directors effective at the 2026 annual meeting of stockholders, filling the vacancy from Pamela S. Seymon's resignation effective the same date, with Ms. Moskowitz's term expiring at the 2027 annual meeting. The Board has not yet determined her committee assignments. As previously announced, Manuel Bronstein will stand for election to the Board at the 2026 annual meeting.

• ·No arrangement or understanding between Ms. Moskowitz and any other person for her selection as director.
• ·No related party transactions involving Ms. Moskowitz reportable under Item 404(a) of Regulation S-K.
• ·Ms. Moskowitz will participate in the Company's non-employee director compensation program as described in Exhibit 10.26 to the Form 10-K filed February 26, 2026.

30-04-2026

ARMOUR Residential REIT, Inc. held its 2026 Annual Meeting on April 30, 2026, where stockholders elected all eight director nominees with strong majorities (e.g., Scott J. Ulm received 50,758,487 For votes), ratified Deloitte & Touche LLP as independent auditors for fiscal year 2026 (80,520,125 For), approved 2025 executive compensation on an advisory basis (48,910,162 For), selected annual frequency for future advisory votes (50,596,296 for one year), and approved the Fourth Amended and Restated 2009 Stock Incentive Plan increasing authorized Common Stock shares by 1,000,000 (49,418,684 For). Voting turnout represented 83,300,043 shares or 67.85% of 122,767,466 outstanding shares. All proposals passed decisively with no significant opposition.

• ·Proxy statement filed March 19, 2026; record date March 6, 2026.
• ·Fourth A&R Plan effective April 30, 2026, terminates April 29, 2036.
• ·Plan adjusts per-share limits from 750,000 to 150,000 post 1-for-5 reverse stock split in September 2023; adds clawback provision.

30-04-2026

ResMed announced that Chief Financial Officer Brett Sandercock plans to retire effective May 4, 2026, after 27 years with the company including 20 as CFO, with Aaron Bloomer appointed as his successor from Exact Sciences. Bloomer brings 17 years of global finance experience, including roles at Baxter International and 3M, and is expected to support the 2030 strategy. ResMed reported Q3 FY26 results and is reiterating FY26 outlook with gross margins of 62-63%, SG&A at 19-20%, R&D at 6-7%, and effective tax rate of 21-23%.

• ·Brett Sandercock to serve as advisor to CEO through end of 2027
• ·ResMed envisions improving more than 500 million lives through sleep and breathing technologies

30-04-2026

At the 2026 Annual Meeting of Stockholders on April 28, 2026, RPC, Inc. shareholders elected ten directors to the Board, including the reelection of Gary Kolstad, who was subsequently appointed to the Audit Committee and as Chairman of the Human Capital Management and Compensation Committee. Shareholders ratified the appointment of Grant Thornton LLP as independent auditor, approved a non-binding say-on-pay vote, ratified prior performance stock unit grants to the CEO and Executive Chairman, and approved amendments to the 2024 Stock Incentive Plan, though the latter faced notable opposition with 54,634,966 against votes compared to 142,609,503 for.

• ·Broker non-votes ranged from 10,667,741 to 11,607,496 across proposals.
• ·Highest against votes for directors: Amy R. Kreisler (30,107,361 against), Timothy C. Rollins (26,924,573 against).
• ·CEO performance stock units ratification: 5,227,438 against, 61,726 abstain.
• ·Executive Chairman performance stock units ratification: 5,232,749 against, 69,299 abstain.

30-04-2026

On April 28, 2026, Scott C. Selbach retired as Executive Vice President, Government Relations & Secretary after more than 35 years of service. Jonathan R. Collins submitted and had accepted his resignation as a director, effective immediately after the April 29, 2026 Annual Meeting, with the Board fixing the number of directors at seven; the resignation was not due to any disagreements. At the Annual Meeting, shareholders elected Sheryl D. Palmer and Jesse G. Singh as directors, approved on an advisory basis the 2025 named executive officer compensation, and ratified Deloitte & Touche LLP as independent auditors, with strong majorities for all proposals though some votes against.

• ·Annual Meeting held on April 29, 2026.
• ·Proxy statement filed March 17, 2026.
• ·Board fixed number of directors at seven.

30-04-2026

USA Compression Partners, LP announced the appointment of Jim S. Holotik as a director on the board of directors of its General Partner, USA Compression GP, LLC, effective April 28, 2026, by Energy Transfer LP, the sole member of the General Partner. Mr. Holotik, an outside director, will receive compensation pursuant to the General Partner’s outside director compensation policy, including an initial award of 2,500 phantom units, with no arrangements or disclosable relationships under Item 404(a) of Regulation S-K.

• ·Appointment made by Energy Transfer LP as sole member of USA Compression GP, LLC.
• ·Compensation policy details described in Form 10-K filed February 17, 2026.
• ·No relationships between Mr. Holotik and the General Partner or Partnership requiring disclosure under Item 404(a) of Regulation S-K.

30-04-2026

On April 26, 2026, FDEE Consulting, Inc., a wholly owned subsidiary of Fluor Corporation, entered into a Consulting Agreement with Mark E. Fields, the company's former Group President, Strategic Projects, for advisory and consultation services at a rate of $670 per hour for up to six months beginning April 27, 2026. The full text of the Consulting Agreement will be filed as an exhibit to Fluor Corporation's quarterly report on Form 10-Q for the quarter ended June 30, 2026. This arrangement follows Mr. Fields' departure from his officer position.

• ·Consulting Agreement filed as part of Form 8-K dated April 30, 2026, under Item 5.02.

30-04-2026

Recursion Pharmaceuticals (NASDAQ: RXRX) announced that founder and current Board Chair Chris Gibson, Ph.D., will complete his term through June 2026 and will not seek re-election, transitioning to a strategic advisor role. CEO Najat Khan, Ph.D., and Vice-Chair Rob Hershberg, M.D., Ph.D., expressed gratitude for his contributions and confidence in continued leadership stability and value creation. The company emphasized its focus on advancing the Recursion OS platform and pipeline in oncology, rare disease, neuroscience, and immunology.

• ·Platform infrastructure anchored in Salt Lake City, Utah and Milton Park, Oxfordshire.
• ·Additional offices in New York, Montréal, and London.

30-04-2026

Teleflex Incorporated (NYSE: TFX) announced the appointment of Jason Weidman as President and Chief Executive Officer effective June 8, 2026, succeeding Stuart Randle, who served as Interim President and CEO since January 2026 and will continue as a Board member. Weidman, with over 25 years in medical technology including senior roles at Medtronic plc overseeing multi-billion dollar units, joins amid planned divestitures, a $1 billion share buyback, and $800 million debt paydown to strengthen the capital structure and focus on core markets. Dr. Stephen Klasko, Chairman, highlighted Weidman's fit for driving growth in interventional, critical care, and high acuity hospital segments.

• ·Jason Weidman previously held roles at Medtronic from 2006-2026, including SVP and President, Coronary & Renal Denervation, and SVP and President, Aortic, Peripheral and Venous.
• ·Weidman's education: MBA in Health Care Management (Wharton School, University of Pennsylvania), MS in Mechanical Engineering with Biomechanics concentration (Stanford University), BSE in Mechanical Engineering (University of Michigan).
• ·Investor contact: Lawrence Keusch, investor.relations@teleflex.com, 610-948-2836.

30-04-2026

Wells Fargo & Company held its 2026 Annual Shareholder Meeting on April 28, 2026, where all 12 director nominees were elected with strong support (93.92% to 98.60% FOR). Shareholders approved the amendment and restatement of the 2022 Long-Term Incentive Plan (95.93% FOR), ratified KPMG LLP as independent auditors for 2026 (93.60% FOR), and passed the advisory vote on executive compensation (65.53% FOR), though the latter received comparatively lower support. All six shareholder proposals failed, with FOR votes ranging from 1.76% to 47.94%.

• ·Shareholder proposals included: Independent Chair (33.90% FOR), Govern by Majority Vote (47.94% FOR), Energy Supply Ratio (20.36% FOR), Report on High-Carbon Financing Litigation Risk (9.19% FOR), Board Committee on Indigenous Peoples' Rights (5.27% FOR), Report on Respecting Vendor Civil Liberties (1.76% FOR).

30-04-2026

Select Medical Holdings Corporation reported Q1 2026 revenue growth of 5.0% YoY to $1,421.5 million, driven by strong 14.5% growth in the rehabilitation hospital segment, but income from operations declined 12.7% to $98.4 million, net income fell to $63.8 million, and Adjusted EBITDA dropped to $141.6 million, with the critical illness recovery segment showing flat 0.3% revenue growth and declining EBITDA margin to 11.5%. The company announced a merger agreement on March 2, 2026, to be acquired by a consortium led by Executive Chairman Robert A. Ortenzio and WCAS XIV, L.P. for $16.50 per share in cash, expected to close mid-2026 pending approvals. It declared a $0.0625 per share cash dividend payable May 28, 2026, and maintained its full-year 2026 outlook for revenue of $5.6B to $5.8B.

• ·Hart-Scott-Rodino waiting period expired April 27, 2026.
• ·Merger closing expected middle of 2026, subject to stockholder and healthcare regulatory approvals.
• ·Q1 2026 diluted EPS $0.35 vs $0.44 prior year; adjusted EPS $0.36 vs $0.44.
• ·Dividend record date May 14, 2026; payment on or about May 28, 2026.
• ·FY2026 outlook: fully diluted EPS $1.22 to $1.32.

30-04-2026

NEXGEL, Inc. (NASDAQ: NXGL) appointed Ian Blackman, CPA, as Chief Financial Officer effective April 27, 2026, to advance the closing and integration of its definitive agreement to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc. (NASDAQ: CELU). Blackman brings over 30 years of finance experience, including driving over 90% revenue growth and over 335% EBITDA growth at McIntosh Group in his most recent role. CEO Adam Levy emphasized Blackman's expertise in scaling businesses and complex transactions to support NEXGEL's growth in healthcare, beauty, and OTC hydrogel products.

• ·Ian Blackman holds a bachelor’s degree in Economics from the London School of Economics.
• ·Blackman began his career in audit at Goldstein Golub Kessler and Company.

30-04-2026

TELA Bio, Inc. furnished preliminary unaudited financial data for the quarter ended March 31, 2026, noting it is subject to change upon financial closing procedures and not audited by KPMG LLP, with full results to be in the upcoming 10-Q. Multiple directors including Chairman Doug Evans, Kurt Azarbarzin, Vince Burgess, and Federica O’Brien will resign effective after the 2026 Annual Meeting, while Joseph Capper is nominated as new non-independent Chairman and Guido Neels, Guy Nohra, and Paul Thomas are appointed as independent directors with committee roles. No specific financial metrics were disclosed, and none of the departures stem from disagreements on company matters.

• ·Resignations effective immediately following 2026 Annual Meeting; no disagreements with company.
• ·Joseph Capper not independent under Nasdaq rules; Incoming Directors (Neels, Nohra, Thomas) are independent.
• ·Equity awards to new directors: options for 17,550 shares (36 monthly installments) and RSUs for 11,925 shares (3 annual installments), effective June 9, 2026.
• ·Committee assignments: Neels (Compensation, Nominating); Nohra (Audit, Chair Compensation); Thomas (Audit, Chair Nominating).
• ·Preliminary Q1 2026 financials unaudited, not reviewed by KPMG, not for reliance.

30-04-2026

Aspira Women's Health Inc. appointed John Strahley as Chief Financial Officer and Chief Accounting Officer effective April 27, 2026, following the termination of Brian Hungerford's consulting agreement as prior CFO on April 26, 2026 for personal reasons. Mr. Strahley, with prior CFO experience at life science firms like IsoPlexis Corporation, will serve in a fractional capacity with an annualized base salary of $167,000 and a grant of options for 70,000 shares. No other arrangements, family relationships, or related transactions were disclosed.

• ·Mr. Strahley, age 59, to devote minimum 20 hours per week; not eligible for company health, dental, vision, or life insurance plans.
• ·Stock options: 25% vest 90 days after start date; remaining 75% in equal monthly installments over next 9 months; full acceleration upon Change in Control.
• ·Employment at-will with no severance or post-termination benefits beyond accrued obligations.
• ·Employment Agreement to be filed as exhibit to Q2 2026 10-Q.

30-04-2026

Planet 13 Holdings Inc. appointed Nancy Saitta and Leilani Bradford as independent directors effective April 24, 2026, to fill two newly created seats on the Board. Both directors were appointed to the Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee, and will receive compensation consistent with other non-employee directors. There are no related arrangements or reportable transactions under Item 404(a) of Regulation S-K.

• ·Company is an emerging growth company.
• ·Filing date: April 30, 2026.
• ·Date of earliest event reported: April 24, 2026.

30-04-2026

Processa Pharmaceuticals, Inc. approved a transition for Dr. Sian Bigora, its Chief Development and Regulatory Officer, from full-time executive officer to part-time employee effective May 1, 2026, as part of her planned retirement. She will no longer be designated as an executive officer under Section 16 of the Exchange Act but will retain her title and provide services in a reduced capacity, with her existing employment agreement replaced by a new part-time arrangement. Dr. Bigora remains eligible for previously granted equity awards and bonus compensation per their original terms.

• ·Date of earliest event reported: April 30, 2026
• ·Filing signed by George Ng on April 30, 2026
• ·Common Stock: $0.0001 par value per share, traded as PCSA on Nasdaq

30-04-2026

Vuzix Corporation granted 477,178 restricted stock units (RSUs) to CEO Paul Travers and 193,258 RSUs to CFO Grant Russell on April 29, 2026, under the 2023 Equity Incentive Plan. The grants consist of 50% time-based vesting (1/3 on December 15 each of 2026, 2027, and 2028) and 50% performance-based vesting (potentially up to 150% of that portion, or 75% of total) through December 31, 2028.

• ·Common Stock par value $0.001, traded as VUZI on Nasdaq Capital Market
• ·Time-based vesting: 1/3 on Dec 15, 2026; 1/3 on Dec 15, 2027; 1/3 on Dec 15, 2028
• ·Performance-based vesting achievable up until Dec 31, 2028

30-04-2026

Amtech Systems, Inc. appointed Thomas Sabol, age 67 with over 30 years of financial leadership experience including multiple CFO roles at public companies like Rimini Street and Plexus Corp., as permanent Chief Financial Officer effective May 14, 2026, replacing interim CFO Mark Weaver. Sabol will receive an annual base salary of $350,000, eligibility for a 50% target bonus (60% cash, 40% restricted stock), and a grant of 45,000 stock options vesting over three years. The appointment includes severance provisions for change in control (12 months base salary and full equity acceleration) and termination without cause (3 months base salary).

• ·Offer letter dated April 17, 2026; Board approval on April 24, 2026; effective date May 14, 2026
• ·No family relationships or material interests under Item 404(a) of Regulation S-K
• ·Sabol's prior roles: Interim CFO and Head of HR at Korn Ferry (Aug 2025-May 2026); Consultant (May 2023-May 2026); CFO at Corcentric (Oct 2021-Mar 2023); CFO at Transact Campus (Nov 2019-Dec 2020); CFO then COO/EVP at Rimini Street (2016-2019) and Plexus (1996-2003)

30-04-2026

Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) appointed Mark Graff as Chief Financial Officer effective May 4, 2026, succeeding Chris Meyer, who served as Interim CFO since December 2025. Graff brings over a decade of experience at Bloomin’ Brands, including leading a $900M Bonefish Grill and Fine Dining business across more than 220 restaurants. CEO Dave Pace emphasized Graff's role in advancing the First Choice Plan and thanked Meyer for providing interim leadership.

• ·Mark Graff previously held senior roles in finance, strategy, investor relations, global business development, capital planning, and M&A at Bloomin’ Brands.
• ·Graff holds a bachelor’s degree from The Pennsylvania State University.
• ·Appointment announced April 29, 2026; SEC filing date April 30, 2026.

30-04-2026

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, to lead financial operations, strategy, capital allocation, corporate development, and investor relations, reporting to Helen Torley, President and CEO. Mr. Snellgrove brings over 30 years of experience, including recent roles at Johnson & Johnson leading investor relations and serving as CFO of its Pharmaceuticals sector generating more than $50 billion in annual revenue. The move is positioned to accelerate value creation for shareholders amid Halozyme's strong technology portfolio including ENHANZE®.

• ·ENHANZE® licensed to partners across over 100 global markets
• ·Halozyme headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA
• ·Hypercon™ licensed to Janssen, Eli Lilly, argenx, and Vertex Pharmaceuticals